Janux Therapeutics, Inc. Cash Flow Statement
JANX / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Janux Therapeutics, Inc. used $82M in operating cash flow and negative free cash flow of $83M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$113.6M | -$69.0M | -$58.3M | -$63.1M | -$32.7M | -$6.8M |
| Depreciation & Amortization | $2.0M | $2.1M | $2.0M | $841.0K | $113.0K | $13.0K |
| Operating Cash Flow | -$82.2M | -$43.8M | -$50.6M | -$42.9M | -$17.0M | -$4.4M |
| Capital Expenditures | $1.0M | $359.0K | $1.9M | $6.4M | $1.5M | $0 |
| Free Cash Flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M | -$18.5M | -$4.4M |